Preclinical News and Research

RSS

Researchers to investigate new drugs for parasitic disease

Urgently-needed new treatment for a parasitic disease is being investigated in research led at the University of Strathclyde in Glasgow, Scotland. Human African Trypanosomiasis, also known as sleeping sickness, affects between 50,000 and 70,000 people in Africa and South America. It is transmitted through the bite of the tsetse fly and attacks the nervous system and brain, leading to fever, headaches and disturbed sleep patterns.

30 Oct 2010

Idera presents data on TLR 3 agonist as vaccine adjuvants at Immunological Meeting

Idera Pharmaceuticals, Inc. today announced a presentation describing the chemistry and immunological activity of its proprietary Toll-Like Receptor (TLR) 3 agonist compounds and the use of these compounds as vaccine adjuvants in a preclinical model.

30 Oct 2010

Merck reports $342 million net income for 2010 third quarter

Merck & Co., Inc. today announced financial results for the third quarter of 2010. The company reported non-GAAP (generally accepted accounting principles) earnings per share (EPS) for the third quarter of $0.85, which excludes purchase accounting adjustments, restructuring costs, merger-related expenses and a $950 million legal reserve.

29 Oct 2010

Compugen signs oncology research collaboration agreement with Seattle Genetics

Compugen Ltd. announced today that it has signed a research collaboration agreement with Seattle Genetics, Inc., USA, covering a Compugen-discovered oncology target. The agreement provides Seattle Genetics with an initial evaluation period and an option for an exclusive worldwide milestone and royalty bearing license for development and commercialization of monoclonal antibody therapeutics addressing this novel target.

29 Oct 2010

Novel small molecule inhibitors may provide new therapy for colon cancer

Researchers are one step closer to providing a new therapy for colon cancer, after findings revealed that a small molecule focal adhesion kinase (FAK) inhibitor known as Y15 effectively blocked cell viability, promoted detachment and apoptosis, and decreased tumor growth in mice. These findings were presented at the American Association for Cancer Research special conference on Colorectal Cancer: Biology to Therapy, held Oct. 27-30, 2010.

29 Oct 2010

University of Maryland to establish major research enterprise for autoimmune diseases

With a new $45 million private gift from the family of a grateful patient, the University of Maryland School of Medicine is planning to establish the nation's only major research enterprise devoted to the study of autoimmune and inflammatory diseases such as celiac disease, multiple sclerosis, chronic obstructive pulmonary disease, asthma and Type 1 diabetes. The gift, from Indiana couple Ken and Shelia Cafferty, is the largest private donation in the history of the University System of Maryland.

29 Oct 2010

Prominent scientist in mitochondrial genetics joins Children's Hospital to establish CMEM

Douglas C. Wallace, Ph.D., a pioneer and internationally prominent scientist in the field of human mitochondrial genetics, has joined The Children's Hospital of Philadelphia to continue his investigations into the role of mitochondrial energy in health and disease.

29 Oct 2010

Researchers identify small-molecule inhibitors that effectively target FAK enzyme in colon cancer

Researchers have identified two small-molecule inhibitors that effectively targeted the focal adhesion kinase (FAK), an enzyme present in certain cancers that helps tumors thrive and survive.

29 Oct 2010

Geron 2010 third quarter revenue increases from $494,000 to $546,000

Geron Corporation today reported financial results for the three and nine months ended September 30, 2010.

29 Oct 2010

ImmunoGen first quarter net loss increases to $12.9 million

ImmunoGen, Inc., a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced financial results for the three-month period ended September 30, 2010 - the first quarter of the Company's 2011 fiscal year (1QFY11).

29 Oct 2010

Caliper Life Sciences third quarter GAAP revenue decreases 8% to $29.7 million

Caliper Life Sciences, Inc., today reported results for its third quarter ended September 30, 2010. Third quarter GAAP revenue decreased 8% to $29.7 million from $32.2 million in the same period in 2009 as a result of divestitures in 2010 and 2009. Revenue from on-going business increased 10% on a reported basis and 11% on an organic basis.

28 Oct 2010

Celgene third quarter non-GAAP total revenue increases 31% to $908 million

Celgene Corporation announced non-GAAP net income of $349.9 million, or non-GAAP diluted earnings per share of $0.75 for the quarter ended September 30, 2010.

28 Oct 2010

Pharmasset's PSI-938 phase I monotherapy trial shows positive result for HCV treatment

Pharmasset, Inc. reported positive preliminary results today from its phase I monotherapy trial of PSI-352938 for the treatment of chronic hepatitis C (HCV). PSI-938 is a guanosine nucleotide analog polymerase inhibitor in development for the treatment of chronic HCV infection.

28 Oct 2010

BioCryst 2010 third quarter revenue increases from $10.5 million to $12.0 million

BioCryst Pharmaceuticals, Inc. announced financial results for the third quarter and nine months ended September 30, 2010.

28 Oct 2010

The Methodist Hospital Research Institute opens 12-story, 440,000 square foot research facility

The Methodist Hospital Research Institute® (TMHRI) today opened a 12-story, 440,000 square foot research facility dedicated solely to research and equipped with the world's most advanced technology to help research scientists, physicians and engineers cure diseases that afflict today's patients.

28 Oct 2010

Lotus receives Chinese SFDA approval for R-Bambuterol Hydrochloride Phase I human clinical trials

Lotus Pharmaceuticals, Inc., a fast-growing, profitable developer, manufacturer and seller of medicine and drugs in the People's Republic of China ("PRC"), announced today that it received approval from the State Food and Drug Administration ("SFDA") Ethics Committee to commence Phase I human clinical trials of R-Bambuterol Hydrochloride, the Company's proprietary drug candidate for the treatment of asthma.

28 Oct 2010

Vical to present preclinical results of HSV-2 vaccine program at Keystone Symposium

Vical Incorporated today announced that the company's Vice President of Clinical Development, Richard T. Kenney, M.D., is presenting preclinical results from the company's herpes simplex type 2 (HSV-2) vaccine program in a poster session Friday morning at the Keystone Symposium on Immunological Mechanisms of Vaccination (Seattle, October 27 – November 1).

27 Oct 2010

Intellect obtains initial draft report of OXIGON Phase 1b clinical trial for Alzheimer’s disease

Intellect Neurosciences, Inc. a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and licenses with major pharmaceutical companies covering products in late-stage clinical trials, announced that it has obtained an initial draft report of the Company's Phase 1b clinical trial for its lead Alzheimer's candidate, OXIGON (OX1).

27 Oct 2010

New International malaria research consortium to develop novel classes of antimalarials

Research teams from three academic institutions and two private sector companies on two continents have come together to form the International malaria research consortium for the development of novel classes of antimalarials. This bold initiative will develop novel classes of drugs against malaria, a deadly disease in desperate need of new treatments.

27 Oct 2010

HIFU technology effective for treating metastatic liver cancer

EDAP TMS SA the global leader in therapeutic ultrasound, reported today successful completion of the first phase of the clinical protocol aimed at evaluating High Intensity Focused Ultrasound (HIFU) technology in patients with metastatic liver cancer. HIFU has the potential to destroy liver tumors through ablation and to reduce bleeding during surgery.

27 Oct 2010

Preclinical News and Research

Researchers to investigate new drugs for parasitic disease

Idera presents data on TLR 3 agonist as vaccine adjuvants at Immunological Meeting

Merck reports $342 million net income for 2010 third quarter

Compugen signs oncology research collaboration agreement with Seattle Genetics

Novel small molecule inhibitors may provide new therapy for colon cancer

University of Maryland to establish major research enterprise for autoimmune diseases

Prominent scientist in mitochondrial genetics joins Children's Hospital to establish CMEM

Researchers identify small-molecule inhibitors that effectively target FAK enzyme in colon cancer

Geron 2010 third quarter revenue increases from $494,000 to $546,000

ImmunoGen first quarter net loss increases to $12.9 million

Caliper Life Sciences third quarter GAAP revenue decreases 8% to $29.7 million

Celgene third quarter non-GAAP total revenue increases 31% to $908 million

Pharmasset's PSI-938 phase I monotherapy trial shows positive result for HCV treatment

BioCryst 2010 third quarter revenue increases from $10.5 million to $12.0 million

The Methodist Hospital Research Institute opens 12-story, 440,000 square foot research facility

Lotus receives Chinese SFDA approval for R-Bambuterol Hydrochloride Phase I human clinical trials

Vical to present preclinical results of HSV-2 vaccine program at Keystone Symposium

Intellect obtains initial draft report of OXIGON Phase 1b clinical trial for Alzheimer’s disease

New International malaria research consortium to develop novel classes of antimalarials

HIFU technology effective for treating metastatic liver cancer

Event guide: 4th LNP Formulation & Process Development Summit eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics